Section Arrow
AGIO.NASDAQ
- Agios Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/16 11:09 EST
Regular Hours
Last
 43.65
+1.11 (+2.61%)
Day High 
44.29 
Prev. Close
42.54 
1-M High
44.55 
Volume 
848.75K 
Bid
43.5
Ask
43.65
Day Low
41.3401 
Open
41.89 
1-M Low
38.9 
Market Cap 
2.48B 
Currency USD 
P/E 3.55 
%Yield -- 
10-SMA 41.63 
20-SMA 42.18 
50-SMA 40.13 
52-W High 62.45 
52-W Low 23.415 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.01/-7.35
Enterprise Value
2.52B
Balance Sheet
Book Value Per Share
22.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
36.50M
Operating Revenue Per Share
0.41
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/16 11:09 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.